98. Eosinophilic gastrointestinal disease Clinical trials / Disease details


Clinical trials : 172 Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04849390
(ClinicalTrials.gov)
June 29, 20212/4/2021A Study to Investigate the Efficacy and Tolerability of ESO-101 in Patients With Eosinophilic EsophagitisA Randomized, Placebo-controlled, Double-blind Trial Evaluating the Efficacy, Tolerability and Safety of ESO-101 in Adult Patients With Active Eosinophilic EsophagitisEosinophilic EsophagitisDrug: ESO-101;Drug: PlaceboEsoCap AGFGK Clinical Research GmbH;FGK Representative Service B.V.Recruiting18 Years70 YearsAll42Phase 2Germany;Netherlands;Spain;Switzerland
2EUCTR2020-000082-16-DE
(EUCTR)
21/01/202129/07/2020A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagusA randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis Active eosinophilic esophagitis
MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eosinophilic oesophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: ESO-101
Product Code: ESO-101
INN or Proposed INN: mometasone
Other descriptive name: MOMETASONE FUROATE
EsoCap AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
42Phase 2Spain;Netherlands;Germany;Switzerland
3EUCTR2020-000082-16-NL
(EUCTR)
29/10/202003/09/2020A study to investigate the efficacy and tolerability of the drug ESO-101 in adult patients with inflammation of the esophagusA randomized, placebo-controlled, double-blind trial evaluating the efficacy, tolerability and safety of ESO-101 in adult patients with active eosinophilic esophagitis Active eosinophilic esophagitis
MedDRA version: 20.1;Level: PT;Classification code 10064212;Term: Eosinophilic oesophagitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: ESO-101
Product Code: ESO-101
INN or Proposed INN: mometasone
Other descriptive name: MOMETASONE FUROATE
EsoCap AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
42Phase 2Spain;Germany;Netherlands;Switzerland